Dr. Levy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1065Fax+1 214-370-1190
Summary
- Dr. Moshe Levy is a hematologist in Dallas, TX and is affiliated with multiple hospitals in the area, including Baylor University Medical Center and Medical City Dallas. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 18 years. He specializes in hematologic oncology and is experienced in hodgkin's lymphoma and leukemia. He has more than 20 publications and over 500 citings.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
UPMC Medical EducationResidency, Internal Medicine, 1999 - 2002
University of Wisconsin School of Medicine & Public HealthClass of 1999
Certifications & Licensure
TX State Medical License 2008 - 2025
MD State Medical License 2002 - 2010
PA State Medical License 2000 - 2002- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01 - Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.Ehab L Atallah, Michael J Mauro, Koji Sasaki, Moshe Y Levy, Paul Koller
Future Oncology. 2024-01-01 - 46 citationsElranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria
Nature Medicine. 2023-10-01
Lectures
- Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-cell Lymphoma and Other NON-Hodgkin’s B-cell Lymphomas – a Phase 2 StudyDecember 2021
Press Mentions
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial ResultsAugust 13th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
